deltatrials
Recruiting PHASE2 INTERVENTIONAL 3-arm NCT05222529

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

A Phase II, Double-blind, Randomized, Multiple Dose, Cross Over, Three-treatment, Three-period, Six Sequence Placebo Controlled Trial to Evaluate Efficacy, Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety and Tolerability of Glycopyrronium (Bromide) in Children From 6 to Less Than 12 Years of Age With Asthma.

Sponsor: Novartis Pharmaceuticals

Conditions Asthma
Interventions Glycopyrronium bromide 12.5ug Glycopyrronium bromide 25ug Placebo
Updated 27 times since 2022 Last updated: Feb 18, 2026 Started: Aug 29, 2022 Primary completion: Jul 30, 2027 Completion: Aug 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Asthma and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 27 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Nov 2022 · 31 days · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Oct 2023 · 4 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

27 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  5. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

▶ Show 22 earlier versions

  1. Jun 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  2. Feb 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  3. Oct 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  6. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  7. Dec 2023 — Jun 2024 [monthly]

    Recruiting PHASE2

  8. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  10. Jun 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  12. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE2

  13. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  14. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  15. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  16. Oct 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  17. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

  19. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

  20. May 2022 — Jun 2022 [monthly]

    Not Yet Recruiting PHASE2

  21. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE2

  22. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Budapest, Hungary , Cape Town, South Africa , Debrecen, Hungary , Eger, Hungary , Esplugues, Spain , George, South Africa , Guatemala City, Guatemala , Ibagué, Colombia , Kaposvár, Hungary and 11 more locations